Detalhe da pesquisa
1.
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Nature
; 575(7781): 217-223, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31666701
2.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med
; 383(13): 1207-1217, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32955176
3.
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Invest New Drugs
; 32(3): 510-7, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24395457
4.
Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects.
Clin Pharmacokinet
; 62(2): 267-275, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529835
5.
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials.
Clin Pharmacol Ther
; 114(2): 371-380, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37150935
6.
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
Bioorg Med Chem Lett
; 21(8): 2394-9, 2011 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21414779
7.
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Clin Cancer Res
; 15(7): 2497-506, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19258444
8.
Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion.
Clin Pharmacol Drug Dev
; 8(1): 22-31, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30256541
9.
Effect of axitinib on the QT interval in healthy volunteers.
Cancer Chemother Pharmacol
; 75(3): 619-28, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25589220
10.
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients.
Cancer Chemother Pharmacol
; 76(3): 567-73, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26198314
11.
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Clin Cancer Res
; 21(8): 1888-95, 2015 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25652454
12.
Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies.
Clin Lymphoma Myeloma Leuk
; 13(4): 385-91, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23763921
13.
Standard Error of Empirical Bayes Estimate in NONMEM® VI.
Korean J Physiol Pharmacol
; 16(2): 97-106, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22563254
14.
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Clin Cancer Res
; 17(21): 6831-9, 2011 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21908572
15.
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci
; 878(30): 3187-92, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20951100
16.
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Cancer Chemother Pharmacol
; 66(2): 357-71, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19967539